## AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims**:

1. (Previously Presented) Pharmaceutical composition for use in the treatment of pain and inflammatory diseases, wherein it comprises a combination of tenatoprazole and one or more anti-inflammatory agents, wherein the anti-inflammatory agent is a nonsteroidal anti-inflammatory agent selected from the group consisting of aspirin, diclofenac, etodolac, indometacin, naproxen, ibuprofen and piroxicam, or a cyclooxygenase-2 inhibitor selected from the group consisting of rofecoxib and celecoxib.

## 2.-5. (Canceled)

- 6. (Currently Amended) Composition according to claim 1, wherein the weight ratio tenatoprazole: anti-inflammatory agent is comprised between 1:2 and 1:40.
- 7. (Previously Presented) Composition according to claim 1, wherein the composition comprises unitary doses each containing from 10 to 60 mg of tenatoprazole and from 10 to 500 mg of anti-inflammatory agent.
- 8. (Original) Composition according to claim 1, wherein tenatoprazole is in the form of a potassium, magnesium, sodium or calcium salt.
- 9. (Previously Presented) Composition according to claim 1, wherein the composition is in a standard form adapted for administration via the oral or the parenteral route.

## 10. -14. (Canceled)

15. (Currently Amended) Composition according to claim <u>1</u> 2, wherein the composition comprises unitary doses each containing from 10 to 60 mg of tenatoprazole and from 10 to 500 mg of anti-inflammatory agent.

16. - 20. (Canceled)

21. (Previously Presented) A medicament for the treatment of pain and inflammatory diseases composed of tenatoprazole and one or more anti-inflammatory agents, wherein the anti-inflammatory agent is a nonsteroidal anti-inflammatory agent selected from the group consisting of aspirin, diclofenac, etodolac, indometacin, naproxen, ibuprofen and piroxicam, or a cyclooxygenase-2 inhibitor selected from the group consisting of rofecoxib and celecoxib.